bremelanotide

Palatin Technologies, Inc. (NYSE: PTN), a biopharmaceutical company that focuses on treatments for diseases with significant unmet medical needs, boasts a lead asset, bremelanotide, that has an "arousing number of major boxes checked," according to H.C. Wainwright. The Analyst H.C....

The positive late-stage results for female arousal drug from Palatin Technologies, Inc. (NYSE: PTN) once again throw light on the underappreciated market of female sexual health. Palatin announced the late-stage study of bremelanotide met its primary endpoint to treat hypoactive sexual desire...

Palatin Technologies, Inc. (NYSE: PTN) spiked dramatically on Friday in response to Thursday's FDA approval of Sprout Pharmaceuticals' female sexual dysfunction drug, flibanserin. Roth Capital analyst Joe Pantginis published a report on Friday predicting that the ruling would reduce...